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Abstract
The hepatocyte growth factor receptor (MET) is a receptor tyrosine kinase (RTK) that has emerged as an important
cancer target. Consequently, a number of different inhibitors varying in specificity are currently in clinical
development. However, to date, it has been difficult to visualize MET expression, intracellular drug distribution and
small molecule MET inhibition. Using a bioorthogonal approach, we have developed two companion imaging drugs
based on both mono- and polypharmacological MET inhibitors. We show exquisite drug and target co-localization
that can be visualized at single-cell resolution. The developed agents may be useful chemical biology tools to
investigate single-cell pharmacokinetics and pharmacodynamics of MET inhibitors.
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Introduction
The most dominant paradigm in drug discovery over the last
two decades has been the design of exquisitely selective
inhibitors that act on a single target within a disease pathway.
However, lack of durable efficacy has challenged this ‘one
gene, one drug, one disease’ hypothesis [1]. This is not entirely
surprising given the robustness of many biological systems and
their ability to utilize redundant networks to overcome inhibition
of a single protein [2]. For these reasons, multi-targeting has
gained renewed interest and indeed many clinically successful
drugs have proven to be less selective than originally thought
[3] [4] [5]. This observation, together with a systems
understanding of cancer pathways has led to the concept of
polypharmacology, i.e. the inhibition of multiple targets within a
cell [2]. While combination therapies are an obvious first step
towards multi-target inhibition, the deliberate design of a single
kinase inhibitor that binds to multiple targets is a newer
development [2] [6].
Receptor tyrosine kinases (RTKs) are key regulators of
critical cellular processes in mammalian development, cell
function and tissue homeostasis [7]. Dysregulation of RTKs has
been implicated as causative factors in the development and
progression of numerous human cancers [7]. Blockbuster
drugs, Gleevec (Bcr-Abl and c-Kit), Herceptin (HER2), and
Iressa (EGFR) have spawned intense investigation of other
RTKs [8]. One of the emerging kinases of interest is the
hepatocyte growth factor receptor (MET), which is widely
expressed in epithelial and endothelial cells. MET is a central
mediator of cell growth, survival, motility, and morphogenesis
during development [9]. Consequently, MET overexpression
relative to normal tissue has been detected in various types of
cancers [10]. In addition, overexpression of MET is indicative of
increased tumor aggressiveness and poor prognosis in cancer
patients [11] [12] [13] [14]. A number of different MET inhibitors
with varying levels of specificity are currently in clinical trials.
These include the monospecific inhibitor, PF04217903, and the
broad-spectrum inhibitor, Foretinib (GSK13630898; inhibits
MET, AXL, RON, PDGFRα, and KDR) [15]. Despite the
growing number of different MET inhibitors and peptide based
whole body imaging agents [16], it has been difficult to
visualize MET expression, intracellular drug distribution and
small molecule MET inhibition.
It is generally believed that imaging is an invaluable tool in
the drug development process. Imaging has been used to
better understand the biology and pathophysiology of human
cancer, enable earlier diagnosis and allow monitoring of
therapeutic drug efficacy. Here we set out to develop a
bioorthogonal imaging agent for high resolution imaging in live
cells, based on clinical small molecule MET inhibitors.
Specifically, we developed a mono-specific MET imaging agent
based on PF04217903 [17] and compared its imaging
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characteristics to an imaging agent based on Foretinib [18], a
polypharmacological MET inhibitor in phase III clinical
development. Using this technique we were able to perform
either very specific MET imaging or single-cell multi-target
imaging of different proteins inside living cells. Companion
imaging drug (CID) development with mono- and
polypharmacologic inhibitors of MET would enable not only
specific visualization of MET but also visualization of multiple
RTKs at single-cell resolution. Such information can potentially
provide new insight for biological understanding of MET and
RTKs and, therefore, could help in the development of new
drug candidates.
Materials and Methods
General experimental procedures
Unless otherwise noted, chemical reactions were carried out
under an atmosphere of nitrogen or argon in air-dried
glassware with magnetic stirring. Air- and/or moisture-sensitive
liquids were transferred via syringe. Organic solutions were
concentrated by rotary evaporation at 25 - 60 °C at 15-30 torr.
Analytical thin layer chromatography (TLC) was performed
using plates cut from glass sheets (silica gel 60 F-254 from
Silicycle). Visualization was achieved under a 254 or 365 nm
UV light and by immersion in an ethanolic solution of cerium
sulfate, followed by treatment with a heat gun. Column
chromatography was carried out as “Flash Chromatography”
using silica gel G-25 (40-63 μM).
Materials
All reagents were obtained from commercial sources and
used without further purification. Dry THF, MeOH, DCM, and
DMF were obtained from Aldrich (St. Louis, MO). Tz-CFDA [19]
and (E)-cyclooct-4-enyl 2,5-dioxopyrrolidin-1-yl carbonate
(TCO-NHS) [20] were synthesized as described earlier.
Histidine-tagged recombinant human MET and AXL, GST-
tagged recombinant Human PDGFRα, the z´-LYTE
Tyrosine-1,4, and 6 peptide assay kits, ER Tracker Red and
Hoechst 33342 were purchased from Invitrogen (Grand Island,
NY). GST-tagged recombinant Human KDR and RON were
purchased from Promega (Madison, WI). PF04217903 and
Foretinib were purchased from Selleck Chemicals (Houston,
TX). RIPA buffer and the MET, phospho-MET (Y1234/1235),
AXL, and PDGFRα antibodies were from Cell Signaling
(Danvers, MA). The RON and KDR antibodies were from
AbCam (Cambridge, MA). Recombinant human hepatocyte
growth factor (HGF) was from Millipore (Billerica, MA).
Odyssey blocking buffer was purchased from LI-COR
Biosciences (Lincoln, NE). HALT protease inhibitor cocktail,
BCA assay, SuperBlock T20 (TBS) blocking buffer, and
SuperSignal West Pico chemiluminescent substrate were from
ThermoScientific Pierce (Rockford, IL).
Instrumentation
1H and 13C NMR spectra were recorded at 23°C on a Varian
400 MHz spectrometers. Recorded shifts are reported in parts
per million (δ) and calibrated using residual undeuterated
solvent. Data are represented as follows: Chemical shift,
multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p =
pentet, m = multiplet, br = broad), coupling constant (J, Hz) and
integration. LC-ESI-MS analysis and HPLC-purifications were
performed on a Waters (Milford, MA) LC-MS system. For LC-
ESI-MS analyses, a Waters XTerra® C18 5 μm column was
used. For preparative runs, an Atlantis® Prep T3 OBDTM 5 μM
column was used (eluents 0.1% TFA (v/ v) in water and MeCN;
gradient: 0-1.5 min, 5-100% B; 1.5-2.0 min 100% B). z´-LYTE
assay fluorescent signal was measured using a Tecan Safire2
microplate system (Männedorf, Switzerland). Data were
analyzed using Prism 6 (GraphPad, La Jolla, CA) for Mac.
Images were collected using a DeltaVision microscope
(Applied Precision, Issaquah, WA).
Chemical synthesis
NMR-spectra of all the products are available. (File S1)
1-((4-fluorophenyl)carbamoyl)cyclopropanecarboxylic
acid (1).  To a solution of cyclopropane-1,1-dicarboxylic acid (2
g, 15.37 mmol) in THF (50 mL), stirred at 0 °C, triethylamine
(2143 µL, 15.37 mmol) was added dropwise. The reaction
mixture was stirred at 0 °C under nitrogen. 30 minutes later,
thionyl chloride (1117 µL, 15.37 mmol) was added dropwise
and the reaction mixture was stirred at 0 °C for additional 30
minutes. Then, toward a turbid reaction mixture, a solution of 4-
Fluoroaniline (1624 µL, 16.91 mmol) in THF (50 mL) was
added dropwise. The reaction mixture was stirred at 0 °C for
1hr. After 1hr stirring, 1N NaOH solution was added. Extraction
with Ethyl Acetate for 3 times and combined organic layer was
dried over MgSO4 and concentrated in vacuo. The resulting
brown solid was washed with cold ethyl acetate to give
compound 1 (1.94 g, 57%) as a white pinkish solid. 1H NMR
(400 MHz, Methanol-d4) δ 7.54 (m, 2H), 7.13 – 6.93 (m, 2H),
1.76 – 1.49 (m, 4H); 13C NMR (101 MHz,) δ 76.4, 169.6, 162.0,
159.6, 135.6 (d, JC,F = 3.0 Hz), 123.3, (d, JC,F = 8.1 Hz) 116.3
(d, JC,F = 23.2 Hz), 27.6, 20.1; LRMS (ESI): m/z calcd for
C11H10FNO3 [M-H]- 222.06, found 222.06.
N-(3-fluoro-4-hydroxyphenyl)-N-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide (2).  To a
solution of 1 (1 g, 4.48 mmol) in DMF (8 drop) and THF (2 mL),
stirred at 0 °C, a solution of oxalyl chloride (2.24 mL, 4.48
mmol) in DCM (1 mL) was added dropwise. The reaction
mixture was stirred at ambient temperature for 2hr. Then, the
solution of 1 and oxalyl chloride in DMF and DCM, was added
to a solution of 4-Hydroxy-3-fluorophenol (626 mg, 4.93 mmol)
and 2,6-Lutidine (519 µL, 4.48 mmol) in THF (2 mL). After
additional stirring at 0 °C, the reaction mixture was gradually
warmed up to ambient temperature. After completion of the
reaction, monitored by TLC and LC-MS, it was quenched by
addition of water. Organic material was extracted with ethyl
acetate 3 times and the combined organic layer was washed
with 1N HCl twice and washed once with NaHCO3 (sat). The
combined organic layer was dried over MgSO4 and
concentrated in vacuo. The resulting crude product was diluted
with ethyl acetate and a brown solid was obtained by filtration
and washed with EA:Hex = 1:3, 1:2 and to 1:1 to give
compound 2 (899 mg, 60%). 1H NMR (400 MHz, DMSO-d6) δ
10.04 (s, 1H), 9.89 (s, 1H), 9.58 (s, 1H), 7.60 (dd, J = 8.9, 5.0
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Hz, 2H), 7.51 (dd, J = 13.4, 2.5 Hz, 1H), 7.16 – 7.06 (m, 3H),
6.85 (t, J = 9.3 Hz, 1H), 1.41 (s, 4H); 13C NMR (101 MHz,
DMSO-d6) δ 168.1, 167.9, 159.4, 157.1, 151.3, 148.9, 140.9
(d, JC,F = 12.1 Hz), 135.2 (d, JC,F = 3.0 Hz), 130.8 (d, JC,F = 9.1
Hz) 122.3 (d, JC,F = 8.1 Hz), 117.0 (dd JC,F = 40.4, 3.0 Hz),
115.0 (d, JC,F = 22.2 Hz), 109.2 (d, JC,F = 23.2 Hz), 31.2, 15.4;
LRMS (ESI): m/z calcd for C17H14F2N2O3 [M-H]- 331.20, found
331.12.
1-(4-(benzyloxy)-3-methoxyphenyl)ethanone (3).  A
solution of 4-Hydroxy-3-methoxyacetophenone (2 g, 12.04
mmol), benzyl bromide (2.26g, 13.24 mmol) and potassium
carbonate (4.99g, 36.11 mmol) in DMF (35mL) was stirred at
45 °C overnight. The next day the reaction mixture was cooled
to room temperature and then poured over ice and the resulting
solid was obtained by filtration. The resulting solid was washed
with water to give compound 3 (3.1 g, quantitative). 1H NMR
(400 MHz, Chloroform-d) δ 7.54 (d, J = 2.0 Hz, 1H), 7.49 (dd, J
= 8.4, 2.1 Hz, 1H), 7.46 – 7.41 (m, 2H), 7.41 – 7.35 (m, 2H),
7.34 – 7.29 (m, 1H), 6.89 (d, J = 8.6 Hz, 1H), 5.23 (s, 2H), 3.94
(s, 3H), 2.54 (s, 3H); 13C NMR (101 MHz, Chloroform-d) δ
196.9, 152.5, 149.6, 136.4, 130.8, 128.8, 128.2, 127.3, 123.2,
112.2, 110.7, 70.9, 56.2, 26.3; LRMS (ESI): m/z calcd for
C16H16O3 [M+H]+ 256.11, found 256.13.
1-(4-(benzyloxy)-5-methoxy-2-nitrophenyl)ethanone
(4).  To a solution of 3 (100 mg, 0.39 mmol) in AcOH (1 mL),
stirred at 0 °C, a nitric acid solution (300 µL, 63.01 mmol) was
added dropwise. The reaction mixture was then warmed up to
ambient temperature and stirred at ambient temperature
overnight. The next day, the reaction mixture was poured over
ice and the resulting solid was obtained by filtration. The
resulting solid was washed with water to give compound 4 (71
mg, 60%). 1H NMR (400 MHz, Chloroform-d) δ 7.66 (s, 1H),
7.48 – 7.31 (m, 5H), 6.76 (s, 1H), 5.22 (s, 2H), 3.97 (s, 3H),
2.49 (s, 3H); 13C NMR (101 MHz) 13C NMR (101 MHz,
Chloroform-d) δ 200.2, 154.7, 148.7, 138.4, 135.3, 133.2,
129.0, 128.7, 127.7, 108.9, 71.5, 56.8, 30.5, 29.8; LRMS (ESI):
m/z calcd for C16H15NO5 [M+H]+ 302.10, found 302.12.
1-(2-amino-4-(benzyloxy)-5-methoxyphenyl)ethanone
(5).  A solution of 4 (1.13 g, 3.76 mmol), iron (841 mg, 15.1
mmol) and ammonium acetate (1.21g, 15.7 mmol) in toluene (1
mL) and water (1 mL) was refluxed overnight. The next day,
the reaction mixture was cooled down to ambient temperature
and iron was removed by filtration through a celite pad. The
resulting filtrate was dissolved with water and extracted with
ethylacetate 3 times. The combined organic layer was dried
over MgSO4 and concentrated in vacuo. Crude product was
purified with silica gel column chromatography to give
compound 5 (911 mg, 89%) as a yellow solid. 1H NMR (400
MHz, Chloroform-d) δ 7.45 – 7.23 (m, 5H), 7.11 (s, 1H), 6.16
(br s, 2H), 6.12 (s, 1H), 5.06 (s, 2H), 3.80 (s, 3H), 2.48 (s, 3H);
13C NMR (101 MHz, Chloroform-d) δ 198.4, 154.7, 147.5,
140.2, 136.1, 128.6, 128.1, 127.2, 115.1, 110.7, 100.9, 70.3,
57.2, 27.7; LRMS (ESI): m/z calcd for C16H17NO3 [M+H]+
272.12, found 272.20.
7-(benzyloxy)-6-methoxyquinolin-4-ol (6).  A solution of 5
(300 mg, 1.11 mmol) and sodium methoxide (239 mg, 4.42
mmol) in dimethoxyethane was stirred at ambient temperature.
After 30 min, ethyl formate (447 µL, 5.53 mmol) was added
dropwise. The reaction mixture was stirred at ambient
temperature overnight. The next day, the reaction mixture was
neutralized with 1N HCl solution. The resulting solid was
obtained by filtration and washed with water to give compound
6 (152 mg, 49%) as a brown solid. 1H NMR (400 MHz,
Methanol-d4) δ 7.85 (d, J = 7.2 Hz, 1H), 7.65 (s, 1H), 7.49 (d, J
= 7.4 Hz, 2H), 7.40 (t, J = 7.4 Hz, 2H), 7.35 (d, J = 7.3 Hz, 1H),
7.06 (s, 1H), 6.28 (d, J = 7.1 Hz, 1H), 5.25 (s, 2H), 3.95 (s, 3H);
13C NMR (101 MHz, DMSO-d6) δ 174.6, 152.0, 147.1, 138.4,
136.1, 135.6, 128.5, 128.1, 128.0, 119.3, 107.3, 104.0, 100.6,
70.0, 55.6, 40.2, 39.9, 39.7, 39.5, 39.3, 39.1, 38.9; LRMS
(ESI): m/z calcd for C17H15NO3 [M-H]- 280.11, found 280.03.
7-(benzyloxy)-6-methoxyquinolin-4-yl
trifluoromethanesulfonate (7).  To a solution of 6 (10 mg,
0.04 mmol), DMAP (0.4 mg, 0.004 mmol) and 2,6-lutdine (8 µL,
0.07 mmol) in dichloromethane (0.3 mL), stirred at -20 °C,
trifluoromethanesulfonyl chloride (5 µL, 0.05 mmol) was added
dropwise. After an additional 5 min stirring at -20 °C, the
reaction mixture was gradually warmed up to ambient
temperature. 3hr later, the reaction mixture was concentrated
in vacuo. Crude product was dissolved with methanol and the
resulting brown solid was obtained by filtration and washed
with water to give compound 7 (15 mg, quantitative) as a light
brown solid. The resulting crude product was used in the next
reaction without further purification or characterization.
N-(4-((7-(benzyloxy)-6-methoxyquinolin-4-yl)oxy)-3-
fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-
dicarboxamide (8).  A solution of 2 (78 mg, 0.27 mmol) and 7
(65 mg, 0.20 mmol) in 2,6-lutdine (1 mL) was refluxed for 7 hr.
After 7 hr stirring, the reaction mixture was cooled down to
ambient temperature and concentrated in vacuo. The crude
product was purified with silica gel column chromatography
(EA:Hex = 1:1 to 3:1) to give compound 8 (67 mg, 58%) as a
white solid. 1H NMR (400 MHz, Chloroform-d) δ 10.26 (s, 1H),
8.96 (s, 1H), 8.33 (d, J = 5.4 Hz, 1H), 7.66 (dd, J = 12.1, 2.4
Hz, 1H), 7.51 (s, 1H), 7.41 – 7.30 (m, 5H), 7.27 (t, J = 7.5 Hz,
2H), 7.23 – 7.16 (m, 2H), 7.09 (t, J = 8.6 Hz, 1H), 6.91 (t, J =
8.6 Hz, 2H), 6.30 (d, J = 5.3 Hz, 1H), 5.16 (s, 2H), 1.63 (q, J =
4.7, 4.1 Hz, 2H), 1.51 (q, J = 5.3, 4.7 Hz, 2H); 13C NMR (101
MHz, Chloroform-d) δ 169.9, 168.6, 161.2, 160.2, 158.8, 155.7,
153.2, 152.1, 150.1, 148.8, 146.8, 137.5 (d, JC,F = 13.1 Hz),
136.5 (d, JC,F = 9.1 Hz), 136.2, 133.0 (d, JC,F = 3.0 Hz), 128.8,
128.2, 127.5, 123.8, 123.2 (d, JC,F = 7.1 Hz), 116.7 (d, JC,F = 3.0
Hz), 115.9 (d, JC,F = 23.2 Hz), 110.1 (dd, JC,F = 23.2, 3.0 Hz),
109.5 (d, JC,F = 2.0 Hz), 102.4 (d, JC,F = 6.1 Hz), 99.8 (d, JC,F =
4.0 Hz), 70.9 (t, JC,F = 4.0 Hz), 56.3 (d, JC,F = 3.0 Hz) 29.23,
17.93; LRMS (ESI): m/z calcd for C34H27F2N3O5 [M-H]- 594.19,
found 594.26.
N-(3-fluoro-4-((7-hydroxy-6-methoxyquinolin-4-
yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-
dicarboxamide(9).  A solution of 8 (20 mg, 0.03 mmol) and 10
% Pd/C (2 mg) in ethanol (0.3 mL) was stirred at 65 °C for 5 hr
under hydrogen. After 5 hr stirring, the reaction mixture was
cooled down to ambient temperature and Pd/C was removed
by filtration through celite pad and concentrated in vacuo.
Crude product was dissolved with ethyl acetate and washed
with water. The combined organic layer was dried over MgSO4
and concentrated in vacuo to give compound 9 (15 mg, 88%)
Bioorthogonal Single-Cell Imaging of MET Inhibitor
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as a yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 9.75 (s, 1H),
9.52 (s, 1H), 9.38 (s, 1H), 7.78 (d, J = 5.1 Hz, 1H), 7.27 (dd, J =
13.2, 2.4 Hz, 1H), 7.07 – 6.98 (m, 2H), 6.93 – 6.85 (m, 2H),
6.77 (t, J = 9.0 Hz, 1H), 6.67 (s, 1H), 6.58 – 6.49 (m, 2H), 5.72
(d, J = 5.1 Hz, 1H), 2.71 (s, 2H), 0.85 (t, J = 2.9 Hz, 4H); 13C
NMR (101 MHz, cdcl3) δ 171.36, 169.94, 168.64, 161.23,
160.17, 158.79, 155.71, 153.22, 152.08, 150.09, 148.80,
146.76, 137.5 (d, JC,F = 13.1 Hz), 136.5 (d, JC,F = 9.1 Hz),
136.20, 133.0 (d, JC,F = 3.0 Hz), 128.80, 128.24, 127.54,
123.83, 123.2 (d, JC,F = 7.1 Hz), 123.12, 116.7 (d, JC,F = 3.0
Hz), 115.9 (d, JC,F = 23.2 Hz), 110.2 (d, JC,F = 3.0 Hz), 110.0 (d,
JC,F = 3.0 Hz), 109.5 (d, JC,F = 2.0 Hz), 102.43, 102.37, 99.8 (d,
JC,F = 4.0 Hz), 70.86, 60.56, 56.3 (d, JC,F = 3.0 Hz), 29.23,
21.17, 17.93, 14.31;LRMS (ESI): m/z calcd for C27H21F2N3O5
[M-H]- 504.14, found 504.18.
tert-butyl 4-(3-bromopropyl)piperazine-1-carboxylate.  A
solution of 1-boc-piperazine (100 mg, 0.54 mmol),
diisopropylethylamine (187 µL, 1.07 mmol) and 1,3-
dibromopropane (164 µL, 1.61 mmol) in 1,4-dioxane (1 mL)
was stirred at 90 °C overnight. The next day, the reaction
mixture was cooled down to ambient temperature and NaHCO3
(sat) was added. Organic material was extracted with
ethylacetate 3 times. The combined organic layer was dried
over MgSO4 and concentrated in vacuo. Crude product was
purified with silica gel column chromatography (MeOH : DCM =
1:20 to 1:10) to give compound tert-butyl 4-(3-
bromopropyl)piperazine-1-carboxylate (107 mg, 65%) . 1H
NMR (400 MHz, Chloroform-d) δ 3.42 (t, J = 6.6 Hz, 2H), 3.39
– 3.34 (m, 4H), 2.44 (t, J = 6.9 Hz, 2H), 2.33 (t, J = 5.1 Hz, 4H),
1.97 (p, J = 6.7 Hz, 2H), 1.40 (s, 9H); 13C NMR (101 MHz,
Chloroform-d) δ 154.7, 79.6, 56.4, 53.0, 31.7, 29.9, 28.5;
LRMS (ESI): m/z calcd for C12H23BrN2O2 [M+H]+ 307.09, found.
tert-butyl 4-(3-((4-(2-fluoro-4-(1-((4-
fluorophenyl)carbamoyl)cyclopropanecarboxamido)pheno
xy)-6-methoxyquinolin-7-yl)oxy)propyl)piperazine-1-
carboxylate (10).  A solution of 9 (15 mg, 0.03 mmol), tert-
butyl 4-(3-bromopropyl)piperazine-1-carboxylate (11 mg, 0.04
mmol) and potassium carbonate (15 mg, 0.11 mmol) in DMF
(0.5 mL) was stirred at 80 °C for 4 hr. After 4 hr stirring, the
reaction mixture was cooled down to ambient temperature and
water was added. Organic material was extracted with
ethylacetate 3 times and the combined organic layer was dried
over MgSO4 and concentrated in vacuo. Crude product was
purified with silica gel column chromatography (MeOH : DCM =
1:20 to 1:10) to give compound 10 (19 mg, 87%). 1H NMR (400
MHz, Chloroform-d) δ 10.11 (s, 1H), 8.48 (s, 1H), 8.39 (d, J =
5.4 Hz, 1H), 7.71 (dd, J = 12.1, 2.5 Hz, 1H), 7.49 (s, 1H), 7.43
– 7.35 (m, 3H), 7.26 – 7.20 (m, 1H), 7.14 (t, J = 8.6 Hz, 1H),
7.03 – 6.94 (m, 2H), 6.34 (dd, J = 5.5, 1.1 Hz, 1H), 4.18 (t, J =
6.5 Hz, 2H), 3.96 (s, 3H), 3.41 (t, J = 5.0 Hz, 4H), 2.57 (t, J =
7.2 Hz, 2H), 2.42 (t, J = 4.9 Hz, 4H), 2.09 (t, J = 6.9 Hz, 2H),
1.77 – 1.68 (m, 2H), 1.62 – 1.53 (m, 2H), 1.39 (s, 9H); 13C NMR
170.0, 168.7, 161.2, 160.2, 158.8, 155.7, 154.9, 153.2, 152.4,
150.0, 148.8, 146.9, 137.5 (d, JC,F = 12.1 Hz), 136.5 (d, JC,F =
9.1 Hz), 133.0 (d, JC,F = 3.0 Hz), 123.8, 123.2 (d, JC,F = 8.1 Hz),
116.7 (d, JC,F = 3.0 Hz), 116.0, 115.8, 115.6, 109.6 (d, JC,F =
22.2 Hz), 108.7, 102.3, 99.7, 79.8, 67.3, 56.3 (d, JC,F = 3.0 Hz),
55.1, 53.1, 29.2, 28.6, 26.4, 17.9.; LRMS (ESI): m/z calcd for
C39H43F2N5O7 [M+H]+ 732.31, found 732.32.
(E)-cyclooct-4-en-1-yl 4-(3-((4-(2-fluoro-4-(1-((4-
fluorophenyl)carbamoyl)cyclopropanecarboxamido)pheno
xy)-6-methoxyquinolin-7-yl)oxy)propyl)piperazine-1-
carboxylate (11).  To a solution of 10 (3 mg, 0.0045 mmol)
and triethylamine (1.25 µL, 0.009 mmol) in DMF (174 µL), a
solution of TCO-NHS (1 mg, 0.0037 mmol) was added in DMF
(100 µL). The reaction mixture was stirred at ambient
temperature for 1 hr was then purified by HPLC to give
compound 11 (1.6 mg, 55%) as a white solid. 1H NMR (400
MHz, Methanol-d4) δ 8.42 (d, J = 5.4 Hz, 1H), 8.29 (s, 2H),
7.83 (dd, J = 12.7, 2.4 Hz, 1H), 7.65 (s, 1H), 7.59 – 7.52 (m,
2H), 7.43 (ddd, J = 9.0, 2.5, 1.2 Hz, 1H), 7.36 (s, 1H), 7.33 (t, J
= 8.8 Hz, 1H), 7.12 – 7.02 (m, 2H), 6.50 (dd, J = 5.4, 1.1 Hz,
1H), 5.69 – 5.42 (m, 2H), 4.42 – 4.32 (m, 1H), 4.28 (t, J = 5.9
Hz, 2H), 3.56 (t, J = 5.2 Hz, 4H), 2.89 (t, J = 7.4 Hz, 2H), 2.76
(t, J = 4.9 Hz, 4H), 2.42 – 2.31 (m, 3H), 2.20 (p, J = 6.6 Hz,
2H), 2.06 – 1.88 (m, 4H), 1.79 – 1.65 (m, 3H), 1.65 – 1.63 (m,
4H); LRMS (ESI): m/z calcd for C43H47F2N5O7 [M+H]+ 784.34,
found 784.35.
5,5-difluoro-7-(3-(4-(3-((4-(2-fluoro-4-(1-((4-
fluorophenyl)carbamoyl)cyclopropanecarboxamido)pheno
xy)-6-methoxyquinolin-7-yl)oxy)propyl)piperazin-1-yl)-3-
oxopropyl)-1,3-dimethyl-5H-dipyrrolo[1,2-c:2',1'-f]
[1,3,2]diazaborinin-4-ium-5-uide (12).  To a solution of 10 (2
mg, 0.0031 mmol) and triethylamine (1.25 µL, 0.009 mmol) in
DMF (119 µL), a solution of BODIPY-FL-NHS (1 mg, 0.0026
mmol) in DMF (219 µL) was added. The reaction mixture was
stirred at ambient temperature for 1 hr and was purified by
HPLC to give compound 12 (1.7 mg, 73.0%) as a yellow solid.
1H NMR (400 MHz, Methanol-d4) δ 8.42 (d, J = 5.4 Hz, 1H),
8.33 (s, 3H), 7.83 (dd, J = 12.6, 2.4 Hz, 1H), 7.64 (s, 1H), 7.60
– 7.51 (m, 2H), 7.47 – 7.39 (m, 2H), 7.39 – 7.28 (m, 2H), 7.11 –
6.98 (m, 3H), 6.50 (d, J = 5.5 Hz, 1H), 6.33 (d, J = 4.0 Hz, 1H),
6.21 (s, 1H), 4.26 (t, J = 5.9 Hz, 2H), 4.01 (s, 3H), 3.73 – 3.56
(m, 4H), 3.21 (t, J = 7.6 Hz, 2H), 2.87 – 2.73 (m, 4H), 2.63 (dt,
J = 14.4, 5.0 Hz, 4H), 2.51 (s, 3H), 2.27 (s, 3H), 2.20 – 2.10 (m,
2H), 1.64 (s, 4H); LRMS (ESI): m/z calcd for C48H48BF4N7O6 [M
+H]+ 906.74, found 906.76.
6-((6-(1-(2-azidoethyl)-1H-pyrazol-4-yl)-1H-
[1,2,3]triazolo[4,5-b]pyrazin-1-yl)methyl)quinoline (13).  To
a solution of PF-0417903 (50 mg, 0.13 mmol) in DMF (1 mL),
stirred at 0 °C, triethylamine (112 µL, 0.81 mmol) was added
dropwise. After 5 min, methanesulfonyl chloride (62 µL, 0.81
mmol) was added. The reaction mixture was gradually warmed
up to ambient temperature. After 1hr stirring at ambient
temperature, sodium azide (157 mg, 2.42 mmol) was added
and the reaction mixture was warmed up to 70 °C and stirred
for 1hr. The reaction mixture was purified by HPLC to give
compound 13 (30 mg, 56%). 1H NMR (400 MHz, Chloroform-d)
δ 8.65 (s, 1H), 8.44 (dd, J = 4.3, 1.7 Hz, 1H), 8.10 (s, 1H), 7.90
(d, J = 7.2 Hz, 2H), 7.65 (d, J = 8.7 Hz, 1H), 7.62 (d, J = 2.0 Hz,
1H), 7.49 (dd, J = 8.8, 2.0 Hz, 1H), 7.12 (dd, J = 8.3, 4.3 Hz,
1H), 5.76 (s, 2H), 4.10 – 3.91 (m, 2H), 3.43 (dd, J = 6.2, 4.8 Hz,
2H); 13C NMR (101 MHz, Chloroform-d) δ 150.1, 148.1, 146.7,
138.9, 136.7, 133.0, 130.9, 129.4, 128.6, 127.9, 127.3, 121.4,
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119.7, 51.1, 50.2, 50.1; LRMS (ESI): m/z calcd for C19H15N11
[M-H+HCO2H]- 442.15, found 442.22.
2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-
b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanamine (14).  A solution
of 13 (30 mg, 0.08 mmol) and palladium charcoal (10 mg) in
MeOH (0.8 mL) and DCM (0.2 mL) was stirred at ambient
temperature under hydrogen atmosphere overnight. The next
day, the palladium charcoal was removed by filtration and the
filtrate was concentrated in vacuo to give compound 14 (34 mg,
quantitative). 1H NMR (400 MHz, DMSO-d6) δ 9.21 (s, 1H),
8.88 (dd, J = 4.2, 1.7 Hz, 1H), 8.65 (s, 1H), 8.40 – 8.33 (m, 1H),
8.31 (s, 1H), 8.01 (d, J = 8.7 Hz, 1H), 7.98 (d, J = 1.9 Hz, 1H),
7.81 (dd, J = 8.8, 2.1 Hz, 1H), 7.52 (dd, J = 8.3, 4.2 Hz, 1H),
6.14 (s, 2H), 4.17 (t, J = 6.2 Hz, 2H), 2.98 (t, J = 6.2 Hz, 2H);
13C NMR (101 MHz, DMSO-d6) δ 151.4, 148.8, 147.7, 147.3,
142.5, 139.0, 138.2, 136.6, 133.9, 131.8, 130.0, 129.9, 128.1,
127.7, 122.4, 119.4, 55.6, 50.5, 42.3; LRMS (ESI): m/z calcd
for C19H15N11 [M-H+HCO2H]- 416.16, found 416.69.
(E)-cyclooct-4-en-1-yl (2-(4-(1-(quinolin-6-ylmethyl)-1H-
[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-
yl)ethyl)carbamate (15).  A solution of 14 (5 mg, 0.01 mmol),
TEA (2 µL, 0.02 mmol) and TCO-NHS (4 mg, 0.02 mmol) in
DMF (0.2 mL) was stirred at ambient temperature for 1 hr. The
reaction mixture was purified by HPLC to give compound 15
(3.1 mg, 44%).
1H NMR (400 MHz, Deuterium Oxide) δ 9.02 (s, 1H), 8.79
(dd, J = 4.3, 1.7 Hz, 1H), 8.39 (s, 1H), 8.32 (dd, J = 8.3, 1.7 Hz,
1H), 8.22 (d, J = 0.7 Hz, 1H), 7.98 (d, J = 8.5 Hz, 2H), 7.87 –
7.80 (m, 1H), 7.52 – 7.44 (m, 1H), 6.12 (s, 2H), 5.39 – 5.17 (m,
2H), 4.24 (t, J = 5.7 Hz, 2H), 4.14 – 4.03 (m, 1H), 3.48 (td, J =
5.9, 2.9 Hz, 2H), 2.13 – 1.99 (m, 2H), 1.75 – 1.40 (m, 6H), 1.34
– 1.22 (m, 2H); LRMS (ESI): m/z calcd for C28H29N9O2 [M+H]+
523.24, found 523.25.
Kinase assays
The IC50 of Foretinib, Foretinib-TCO (11), Foretinib-BODIPY-
FL (12), PF04217903, and PF04217903-TCO (15) were
determined using the z´-LYTE assay kit. The Tyr6 peptide kit
was used to measure MET, RON, and AXL activity. The Tyr4
peptide kit was used for PDGFRα and the Tyr1 peptide kit was
used to measure KDR activity. All assays were run in
accordance with the manufacturer’s instructions, with minor
modification. Briefly, MET, RON, and KDR were used at 0.2
μg/ml, 0.8 μg/ml, and 0.7 μg/ml, respectively. The kinase
reaction buffer for MET, RON, and KDR was supplemented
with 0.67% DMSO. AXL was used at 1.5 μg/ml and the reaction
buffer was supplemented with 0.01% sodium azide and 0.67%
DMSO. PDGFRα was used at 2.5 μg/ml and the reaction buffer
was supplemented with 1mM DTT, 2mM MnCl2, and 0.67%
DMSO. Inhibitors were prepared by 4-fold serial dilution at 75X
the final concentration in 100% DMSO (8 μM to 0.1 nM). This
stock was then diluted to 3X the final concentration in kinase
reaction buffer. 5 μl of the 3X stock was added to the final 15 μl
reaction volume. Both the z´-LYTE control phosho-peptide and
the z´-LYTE peptide were used at a final concentration of 2 μM.
ATP was added at a final concentration of 50 μM for MET and
AXL, 10 μM for RON and PDGFRα and 75 μM for KDR to
initiate the reaction, which proceeded for 1 hour at room
temperature. Development reagent was then incubated for 1
hour at room temperature. After terminating the reaction with
stop reagent, the coumarin and FRET based fluorescein
emission was measured on a TECAN Saffire2 plate reader (ex:
400 nm, em: 445 and 520 nm). IC50 values were obtained by
fitting the dose-response curves using Prism 6 (GraphPad).
Cell lines
HT-29, SK-BR-3, MDA-MB-436, MDA-MB-231, HCC1937,
HCC1395, and HCC38 cells were from ATCC (Manassas, VA).
OVCA429 [21] and A2780 [22] cells were kindly provided by
Dr. Michael Birrer (Massachusetts General Hospital, Boston,
MA). HT-29 and SK-BR-3 cells were maintained in Dulbecco’s
Modified Eagle Medium supplemented with 10% fetal bovine
serum, 100 I.U. penicillin, 100 μg/ml streptomycin, and 2 mM L-
glutamine. All other cell lines were maintained in RPMI 1640
supplemented with 10% fetal bovine serum, 100 I.U. penicillin,
100 μg/ml streptomycin, and 2 mM L-glutamine
Live cell fluorescence microscopic imaging of
Foretinib-TCO and Foretinib-BODIPY-FL
OVCA429 cells were plated at 5000 cells per well in 96-well
black μ-clear bottom plates (Grenier Bio-One) and were grown
for 48-72 hrs. On the day of imaging, cells were incubated with
a final concentration of 40, 200 and 1000 nM (0.1% DMSO in
growth media) of Foretinib-TCO (11) and Foretinib-BODIPY-FL
(12) for 30 min at 37°C. Cells were washed three times with
media (5 min each). In the case of Foretinib-TCO, cells were
then incubated with 1 μM Tz-CFDA (0.1% DMSO in growth
media) for 30 min at 37°C. After washing with media several
times over 2 hrs, live cells were imaged in a humidified
environmental chamber of a DeltaVision microscope using a
40X objective.
Fixed cell fluorescence microscopic imaging of
PF04217903-TCO and Foretinib-TCO with
Immunostaining of MET.
OVCA429 cells were plated at 5000 cells per well in 96-well
black μ-clear bottom plates (Grenier Bio-One) and were grown
for 48-72 hrs. On the day of imaging, cells were incubated with
a final concentration of 40 nM (0.1% DMSO in growth media) of
PF04217903 (15) and 200 nM (0.1% DMSO in growth media)
of Foretinib-TCO (11) for 30 min at 37°C. Cells were washed
three times with media (5 min each) and then incubated with 1
μM Tz-CFDA (0.1% DMSO in growth media) for 30 min at
37°C. Cells were washed with media several times over 2 hrs
and fixed in 2% paraformaldehyde (in PBS) for 10 min at room
temperature. Following 3 washes, 5 min each, with PBST (PBS
with 0.1% Tween-20), cells were permeabilized with 100%
MeOH for 10 min at room temperature. Cells were blocked in
Odyssey Blocking Buffer (LI-COR Biosciences) for 1 hr at room
temperature. Primary antibody staining with a MET (1:3000,
Cell Signaling) was done overnight at 4°C in Odyssey Blocking
Buffer. Following three washes (5 min each) with PBST, cells
were stained with a donkey α-rabbit Alexa Fluor 647
conjugated secondary antibody (1:200, Invitrogen) for 1 hour at
room temperature. Cells were washed once with PBST and
twice with PBS. Cell nuclei were stained with Hoechst 33342
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(Invitrogen). Imaging was done on a DeltaVision microscope
(Applied Precision) using a 40X objective.
Fixed cell fluorescence microscopic imaging of
Foretinib-TCO/Tz-CFDA with Immunostaining of 5
different RTKs
OVCA429 cells were plated at 5000 cells per well in 96-well
black μ-clear bottom plate (Grenier Bio-One, Monroe, NC) and
were grown for 48-72 hrs. On the day of imaging, cells were
incubated with a final concentration of 200 nM (0.1% DMSO in
growth media) of Foretinib-TCO (11) for 30 min at 37°C. Cells
were washed three times with media and were then incubated
with 1 μM Tz-CFDA (0.1% DMSO in growth media) for 30 min
at 37°C. Cells were washed with media several times over 2
hrs and fixed in 2% paraformaldehyde (in PBS) for 10 min at
room temperature. Following 3 washes, 5 min each, with PBST
(PBS with 0.1% Tween-20), cells were permeabilized with
100% MeOH for 10 min at room temperature. Cells were
blocked in Odyssey Blocking Buffer (LI-COR Biosciences) for 1
hr at room temperature. Primary antibody staining with a MET
(1:3000, Cell Signaling), PDGFRα (1:1000, Cell Signaling),
RON (1:50, Abcam), AXL (1:100, Cell Signaling), or KDR
(1:1000, Abcam) antibody was done overnight at 4°C in
Odyssey Blocking Buffer. Following three washes (5 min each)
with PBST, cells were stained with a donkey α-rabbit Alexa
Fluor 647 conjugated secondary antibody (1:200, Invitrogen)
for 1 hour at room temperature. Cells were washed once with
PBST and twice with PBS. Cell nuclei were stained with
Hoechst 33342 (Invitrogen). Imaging was done on a
DeltaVision microscope (Applied Precision) using a 40X
objective.
Live cell fluorescence microscopic imaging of
PF04217903-TCO and Foretinib-TCO
OVCA429 cells were plated at 5000 cells per well in 96-well
black μ-clear bottom plates (Grenier Bio-One) and were grown
for 48-72 hrs. On the day of imaging, cells were incubated with
a final concentration of 40 nM (0.1% DMSO in growth media) of
PF04217903 (15) and 200 nM (0.1% DMSO in growth media)
of Foretinib-TCO (11) for 30 min at 37°C. Cells were washed
three times with media (5 min each) and then incubated with 1
μM Tz-CFDA (0.1% DMSO in growth media) for 30 min at
37°C. After washing with media several times over 2 hrs, live
cells were imaged in a humidified environmental chamber of a
DeltaVision microscope using a 40X objective.
Western blot
OVCA429, SK-BR-3, A2780, MDA-MB-436, MDA-MB-231,
HCC1937, HCC1395, and HCC38 cells were plated in one
35mm well each. 48 hrs after plating, the cells were washed
twice with ice-cold PBS, and scraped in RIPA buffer (Cell
Signaling Technology) containing 1X HALT protease inhibitor
cocktail (ThermoScientific Pierce). Lysates were passed
through a 23g syringe 5 times, sonicated for 40 sec, and
vortexed every min for 5 min to solubilize the proteins. Lysates
were then centrifuged for 15 min at 14,000 x g (4°C). Total
protein from the supernatant was determined using the BCA
assay (ThermoScientific Pierce). Equal amounts of protein from
each cell sample was boiled for 5 min and then run on a 4-12%
Bis-Tris Novex NuPAGE gel (Invitrogen) for 1 hr at 200V.
Protein was transferred to nitrocellulose, which was blocked
using SuperBlock T20 (TBS) buffer. Blots were briefly washed
in TBST (TBS with 0.1% Tween-20). Primary antibodies
against MET (1:2000), RON (1:5000), KDR (1:1000), AXL
(1:1000), or PDGFRα (1:1000) were diluted in 10%
SuperBlock/TBST and incubated overnight at 4°C. Blots were
washed three times, 5 min each, in TBST and then incubated
in goat α-rabbit IgG HRP conjugated secondary antibody
diluted in 10% SuperBlock/TBST. Blots were again washed
three times, 5 min each, in TBST and were detected using
SuperSignal West Pico chemiluminescent substrate
(ThermoScientific Pierce). Blots for MET, RON, and PDGFRα
were from blots that were stripped using RestoreTM western blot
stripping buffer (ThermoScientific).
For analysis of MET phosphorylation following Foretinib
inhibition, OVCA429 cells were plated in 6-well plates 48 hrs
before the assay. Cells were serum-starved in media
containing 0.1% fetal bovine serum ~16 hrs before the assay.
On the day of the assay, 0, 0.1, 0.5, or 1 μM Foretinib,
Foretinib-TCO (11), or Foretinib-BODIPY-FL (12) were diluted
in media containing 1 mg/ml BSA. Cells were incubated with
Foretinib or its derivatives for 1 hr at 37°C. Phosphorylation
was then stimulated with 100 ng/ml HGF diluted in RPMI with 1
mg/ml BSA for 5 min at 37°C. Cell lysates were then prepared
and run on a gel as described above. Western blot analysis
was performed as described above using the MET and
phospho-MET primary antibodies (1:1000). Total MET and
phospho-MET expression was quantified using densitometry
(ImageJ).
Results
Molecular design of mono- and poly-pharmacologic
agents
We have developed a polypharmacologic companion
imaging drug (PCID) using the multi-targeting MET inhibitor,
N1’-[3-fluoro-4-[[6-methoxy-7-(3-morpholinopropoxy)-4-
quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-
dicarboxamide (Foretinib) as a chemical scaffold (Figure 1A)
and a specific MET CID based on the selective MET inhibitor,
2-(4-(3-(quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-
yl)-1H-pyrazol-1-yl)ethanol (PF04217903) (Figure 1B). Crystal
structure analysis indicated that the morpholine residue of
Foretinib is not involved in ligand-protein interaction, is
exposed to the solvent and could therefore be available for
modification with trans-cyclooctene (TCO) (Figure S1). An
amine reactive Foretinib derivative was thus synthesized,
which could act as the starting material for different imaging
agents, as described previously with minor modification (Figure
2). Briefly, chlorination of cyclopropane-1,1-dicarboxylic acid
with thionyl chloride, followed by reaction with 4-fluoroaniline,
resulted in compound 1. Repeating chlorination of 1 with
oxalylchloride and addition of 4-hydroxy-3-fluorophenol yielded
compound 2. Benzyl protection of 4-hydroxy-3-methoxy
acetophenone afforded compound 3 and nitration of 3 with
nitric acid in acetic acid resulted in compound 4. Reduction of 4
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 with iron and ammonium acetate in refluxed toluene and water
resulted in compound 5. Cyclization of compound 5 with
ethylformate in basic condition resulted in 6, and triflation of
compound 6 resulted in compound 7. Coupling of compound 2
and 7 in refluxed 2,6-lutidine afforded compound 8 and benzyl
deprotection by hydrogenation with palladium charcoal gave
compound 9. Coupling of 9 with piperazine derivatives
(prepared by reaction between 1,3-dibromopropane and N-
Boc-piperazine) in basic condition resulted in compound 10.
Finally, the Boc group was deprotected with TFA and the
resulting secondary amine was recovered. The selective MET
intermediate scaffold based on PF04217903 was synthesized
similarly [15] in 3 steps (overall yield of 23%; Figure 2 and
Figure S2A and B).
Characterization of companion imaging drugs
To convert the above amine containing intermediates into
different imaging agents, we pursued two approaches: direct
conjugation to a fluorochrome (BODIPY-FL) and two-step
bioorthogonal clickable reaction via TCO-drug and
tetrazine(Tz)-BODIPY FL. The inhibitory effects of Foretinib,
Foretinib-TCO (11) and Foretinib-BODIPY-FL (12) were
evaluated using a FRET based MET kinase activity assay.
Direct modification of Foretinib with the BODIPY-FL
fluorochrome (12) led to a significant loss in drug activity,
decreasing the IC50 over 24-fold (from 28.7 nM [23] to 697.4
nM; Figure 3A and Table 1). Interestingly, the smaller TCO
modification only modestly impacted the IC50 value of Foretinib
(88.6 nM; Figure 3A and Table 1). To further assess the impact
of the BODIPY-FL (12) and the TCO (11) modifications on
Foretinib activity, Western blot experiments were done for MET
phosphorylation. OVCA429 ovarian cancer cells were pre-
treated with increasing concentrations of Foretinib, Foretinib-
BODIPY-FL (12) or Foretinib-TCO (11). Cells were
subsequently lysed and Western blot analysis was done for
phosphorylated MET, as well as total MET expression (Figure
3B and C). MET exhibited some basal phosphorylation,
consistent with the high overexpression of MET in OVCA429
cells and with previous reports [24]. Stimulation with HGF led to
a significant increase in MET phosphorylation. For total MET
expression, we observed two different MET protein bands, the
145 kDa beta-chain and the unprocessed 170 kDa precursor
[25] [26] [27]. At all concentrations tested, Foretinib treatment
led to a complete decrease in MET phosphorylation. Both
Foretinib-TCO (11) and Foretinib-BODIPY-FL (12) pre-
treatment led to a decrease in MET phosphorylation, with the
TCO (11) modification exhibiting greater potency than the
BODIPY-FL (12) version (Figure 3B and C). This trend is
consistent with the assay using purified MET, but the absolute
inhibitory effect may be different in cell culture due to the
abundance of other targets available for interaction with
Foretinib and its derivatives. Similarly, TCO modification of
PF04217903 (15) showed minimal reduction of the IC50 value
from 0.54 nM to 1.48 nM (Figure S2C). Figure S3 compares
imaging of Foretinib-TCO to Foretinib-BODIPY-FL in OVCA429
ovarian cancer cells. The former showed a dose-dependent
increase in cellular fluorescence signal (Figure S3) whereas
the latter shows cellular staining only at the highest
concentration tested (in addition to or because of its poor target
binding). Collectively, therefore, we confirmed the efficiency of
the two-step bioorthogonal imaging strategy for PCID.
Focusing on the two-step bioorthogonal imaging strategy we
next assessed the affinity of Foretinib-TCO against other target
kinases: AXL, RON, PDGFRα, or KDR. Similar to the results
obtained using purified MET, the TCO (11) modification only
minimally impacted the IC50 value for each of the protein
targets tested (Figure 3D and Table 1). On average, TCO
modification still resulted in an affinity ligand in the low nM
range (Table 1) suggesting its use as a model PCID.
Single-cell distribution of mono- and poly-
pharmacologic companion imaging drugs
Given the affinity and cellular uptake of the bioorthogonal
agents we next determined target localization by fluorescence
microscopy. We chose carboxyfluorescein diactate-tetrazine
(Tz-CFDA) to reveal Foretinib-TCO (11) given prior results in
live cell imaging [15]. These experiments were performed in
OVCA429 ovarian cancer cells because of their high MET
expression as determined by Western blot (Figure S4). We first
tested PF04217903-TCO (15), given its exquisite affinity and
specificity for MET. Compared to antibody co-staining for MET,
there was superb co-localization of the drug and its target
(Figure 4 and Figure S5, Manders correlation coefficient of
colocalization test about selected image was 0.969). A control
experiment with unlabeled Foretinib/Tz-CFDA confirmed the
low background signal as well as specificity of the TCO/Tz
based two-step bioorthogonal labeling technique (Figure S5).
When SK-BR-3 cells that lack MET were used for the same
imaging experiments, PF04217903-TCO (15) showed no
significant staining compared to Foretinib-TCO (11) (Figure 4).
Interestingly, Foretinib-TCO showed a different pattern. In
addition to some membrane staining, there was also significant
other cellular staining within the cell, presumably the
cytoplasm/perinuclear region (Figure 4). Similar staining
patterns were also observed by live cell imaging for both
PF04217903-TCO and Foretinib-TCO (Figure S6). We next
investigated the phenotype of intracellular Foretinib-TCO
distribution (Figure 5). We wanted to better understand the
poly-pharmacologic drug distribution to understand where the
drug localizes. We were specifically interested in determining
whether the observed cellular staining co-localized with any of
the other known Foretinib targets. To further probe the
polypharmacologic distribution of Foretinib, we used correlative
antibody staining against AXL, RON, PDGFRα, KDR, and
MET. Figure 5 summarizes these experiments showing co-
localization of Foretinib-TCO (11) with some of the other known
targets. Consistent with the enzymatic assay result, Foretinib-
TCO (11)/Tz-CFDA shows good co-localization with the
membrane signal from the MET, AXL, and RON antibody
staining (Figure 5). In addition the red fluorescent nuclear
signal from immunostaining with the RON antibody [28] shows
good co-localization with Foretinib-TCO (11)/Tz-CFDA staining.
There was less co-localization with PDGFRα and KDR, likely
due to the low expression of these proteins in OVCA429 cells
(Figure S4). Overall, we observed very good co-localization
between the specific MET inhibitor (PF04217903-TCO) and
Bioorthogonal Single-Cell Imaging of MET Inhibitor
PLOS ONE | www.plosone.org 7 November 2013 | Volume 8 | Issue 11 | e81275
Figure 1.  Crystal structure of MET (gray) showing the design of the bioorthogonal MET imaging agents.  (A) Foretinib-TCO
(B) PF04217903-TCO. Note that the bioorthogonal transcyclooctene (TCO) is predicted to project outside from the target so that it is
available for reaction with the fluorescent counter partner. (PDB ID: 3LQ8 and 3ZXZ) 3D models were rendered using PyMol.
doi: 10.1371/journal.pone.0081275.g001
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MET. In contrast, Foretinib-TCO/Tz-CFDA staining not only
appears in the membrane but also in the cytoplasm as well as
the nucleus. Based on recent kinome studies [29], these
patterns are most likely explained by the very broad inhibition
of > 30 kinases throughout the cell by this compound.
Therefore, our results shows that the Foretinib-TCO (11)/Tz-
CFDA bioorthogonal two-step labeling procedure is useful for
imaging polypharmacologic distribution of drug targets not only
in fixed cells, but also in live cells. Moreover PCID, combining
with the image based phenotypic screening system, will be a
useful chemical tool for new polypharmacologic drug discovery.
Discussion
The ability of many drugs, often unintended, to interact with
multiple proteins is commonly referred to as polypharmacology.
Figure 2.  Synthetic scheme of Foretinib-TCO (11), Foretinib-BODIPY-FL (12) and PF04217903-TCO (15).  Boc = tert-
butyloxycarbonyl; Bn = Benzyl; BODIPY-FL = 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionyl; DMAP = 4-
dimethylaminopyridine; DCM = dichloromethane; DIPEA = N,N-Diisopropylethylamine; DME = dimethoxyethane; DMF =
dimethylformamide; Ms = methanesulfonyl; TCO = trans-cyclooctene; TEA = triethylamine; TFA = trifluoroacetic acid; THF =
tetrahydrofuran; NHS = N-hydroxysuccinimide.
doi: 10.1371/journal.pone.0081275.g002
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Using Foretinib as a model system we show that bioorthogonal
conjugates of the drug can be used to image drug binding to its
multiple targets. Specifically, we i) investigated the IC50 for
most known binding partners and showed them to be similar to
that of the parent drug, ii) showed that the drug distribution
inside single cells can be visualized (important in confirming
target localization) and iii) that cellular images reflect the
distribution and abundance of multiple drug targets (as shown
by Western and comparative selective MET imaging).
The approach shown here has two practical and potentially
far reaching applications: i) synthesis of imageable drug
analogs to study their distribution in vivo and ii) to develop new
multi-target imaging agents that can be translated to whole
body and clinical imaging. While we used a bioorthogonal two-
step procedure for cellular imaging to optimize spatial
resolution we anticipate that the development of small footprint
fluorochromes will ultimately enable in vivo imaging at the
whole body level [30]. This will be further facilitated by the
concurrent development of red-shifted cell permeable
fluorochromes [31], turn-on fluorochromes [32], fluorochromes
with improved pharmacokinetics and fluorochromes that can be
labeled with radioisotopes for PET imaging [33].
Figure 3.  Inhibitory effect of Foretinib based imaging agents.  (A) The IC50 values for Foretinib, Foretinib-TCO (11) and
Foretinib-BODIPY-FL (12) against purified MET were determined using the z’-lyte kinase assay. Note the much lower affinity of the
fluorochrome conjugated drug compared to the bioorthogonal version. (B) Representative western blot of MET phosphorylation
inhibition by Foretinib, Foretinib-TCO (11) and Foretinib-BODIPY-FL(12) in OVCA429 cells. Following pre-treatment with increasing
concentrations of inhibitors (0, 100, 500, or 1000 nM, respectively), MET phosphorylation was stimulated with HGF for 10 min,
followed by cell lysis, SDS-PAGE, and Western blot with MET and phospho-MET antibodies. (C) Densiometric quantification of MET
phosphorylation from the Western blot data using ImageJ. (D) The IC50 values for Foretinib and Foretinib-TCO (11) against purified
AXL, PDGFRα, RON and KDR were determined using the z’-lyte kinase assay. R2 values for the dose-response curve fit
(GraphPad, Prism) were 0.92 or greater.
doi: 10.1371/journal.pone.0081275.g003
Table 1. IC50 values of Foretinib, Foretinib-TCO (11), and Foretinib-BODIPY-FL (12) for the indicated recombinant human
kinases.
Compound MET AXL RON PDGFRα KDR
Foretinib 28.7 21.4 20.2 59.2 24.3
Foretinib-TCO 88.6 72.5 82.7 264.6 149.9
Foretinib-BODIPY-FL 697.4 ND ND ND ND
Fold Change (TCO/Foretinib) 3.1 3.4 4.1 4.5 6.2
All IC50 values are in nM and R2 values for the dose-response curve fit (GraphPad, Prism) were 0.92 or greater. Fold change is Foretinib-TCO (11) IC50 value divided by
Foretinib IC50 value. ND: not determined.
doi: 10.1371/journal.pone.0081275.t001
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Figure 4.  Bioorthogonal labeling using the specific MET CID PF04217903-TCO (15) or the PCID Foretinib-TCO (11) in
OVCA429 (MET positive) and SK-BR-3 (MET negative) cells.  Cells were incubated for 1hr with 200 nM Foretinib-TCO (11) or 40
nM PF04217903-TCO (15), washed and incubated for 30 min with 1 μM Tz-CFDA (e-h) for bioorthogonal reaction inside living cells.
After fixation with 2% paraformaldehyde, MET was labeled using a MET primary antibody and AlexaFluor 647 labeled secondary
antibody (i-l). After nuclear staining with Hoechst 33342 (a-d) for 10 min, 40X images were collected using a DeltaVision
microscope. Note the excellent co-localization between the MET antibody and affinity ligands on the membrane of the cells (m-p).
Scale bar: 10 μm.
doi: 10.1371/journal.pone.0081275.g004
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Figure 5.  OVCA429 cells were incubated for 30 min with 200 nM Foretinib-TCO (11), washed, and incubated for 30 min with
1 μM Tz-CFDA (f-j, green) for bioorthogonal reaction inside living cells.  Cells were subsequently fixed and stained with
antibodies (red) for MET (a,f,k,p), PDGFRα (b,g,l,q), RON (c,h,m,r), AXL (d,i,n,s), and KDR (e,j,o,t). Cell nuclei were stained with
Hoechst 33342 (blue, a-e) for 10 min and 40x images were collected using a DeltaVision microscope. Note that the PCID allows
imaging of multiple targets. Scale bar: 10 μm.
doi: 10.1371/journal.pone.0081275.g005
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Supporting Information
Figure S1.  Molecular design of polypharmacology
companion imaging drugs (PCID) based on the crystal
structures of Foretinib. a) Crystal structure of MET in
complex with Foretinib (PDB ID: 3LQ8). b) Crystal structure
prediction of MET in complex with Foretinib-TCO. 3D models
were rendered using PyMol.
(TIFF)
Figure S2.  Molecular analysis of MET-specific imaging
drugs based on the PF04217903 scaffold. a) Crystal
structure of MET in complex with PF04217903 (PDB ID: 3zxz).
b) Crystal structure prediction of MET in complex with
PF04217903-TCO. 3D models were rendered using PyMol. c)
The IC50 values for PF04217903 and PF04217903-TCO (15)
against recombinant MET were determined using the z′-lyte
kinase assay. Data were fit to a sigmoidal dose-response curve
using GraphPad software (Prism).
(TIFF)
Figure S3.  Comparison of two-step (top row) and one-step
(bottom row) labeling. OVCA429 cells were incubated for 30
min with Foretinib-TCO (11) or Foretinib-BODIPY-FL (12).
Cells were washed and then incubated for 30 min with 1 μM
CFDA-Tz for bioorthogonal reaction inside living cells (a-d
only). 40x images were collected using a DeltaVision
microscope. a–c) Cells were treated with 1000, 200, and 40
nM, respectively, of Foretinib-TCO (11)/Tz-CFDA; d–f) Cells
were treated with 1000, 200 and 40 nM, respectively, of
Foretinib-BODIPY-FL (12). Scale bar: 10 μm.
(TIFF)
Figure S4.  Western blot analysis of MET, PDGFRα, AXL,
RON and KDR expression in 8 different cell lines including,
A2780 (1), OVCA429 (2), SK-BR-3 (3), MDA-MB-436 (4),
MDA-MB-231 (5), HCC1937 (6), HCC1395 (7) and HCC38 (8).
(TIFF)
Figure S5.  MET imaging in OVCA429 cells. Cells were
incubated for 30 min with 40 nM Foretinib (a,b and c),
PF04217903-TCO (15) (d, e and f) or Foretinib-TCO (11) (g, h
and i), washed, and incubated for 30 min with 1 μM Tz-CFDA
for bioorthogonal reaction inside living cells. After fixation with
2% paraformaldehyde, MET was labeled using a MET primary
antibody and AlexaFluor 647 labeled secondary antibody (i-l).
After nuclear staining with Hoechst 33342 (blue nuclei) for 10
min, 40X images were collected using a DeltaVision
microscope. Note the striking co-localization between the
selective MET imaging agent and the MET antibody stain.
Foretinib-TCO shows a much broader intracellular distribution.
Scale bar: 10 μm.
(TIFF)
Figure S6.  Live cell fluorescence microscopic imaging of
Foretinib-TCO (11)/Tz-CFDA (a, b) or PF04217903-TCO
(15)/Tz-CFDA (c, d) in OVCA429 cells. Cells were incubated
for 30 min with 1 μM Foretinib-TCO (11) or 40 nM
PF04217903-TCO (15). Cells were then washed and incubated
for 30 min with 1 μM Tz-CFDA for bioorthogonal reaction inside
living cells. After washing, live cells were imaged in a
humidified environmental chamber of a DeltaVision microscope
using a 40X objective. Scale bar: 10 μm.
(TIFF)
File S1.  NMR-spectra of all the products.
(PDF)
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